Allergan teams with Quintiles for promotion of Sanctura XR

Allergan has announced that it has entered into an agreement with Quintiles which will see the two firms work together to promote Sanctura XR (trospium chloride extended release capsules).

Sanctura is an anticholinergic that has previously been approved for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency.

Under the agreement, Quintiles will arrange a specialised sales force to deal with the distribution of Sanctura XR until the end of December 2011.

Ron Wooten, executive vice-president of corporate development at Quintiles, said: “Allergan and Quintiles are innovators in the life sciences industry, leveraging our core competencies and resources to improve patients’ lives and achieve commercial success to continue investing in scientific advancements.”

In July, fast-track designation for an investigation into Allergan’s non-muscle invasive bladder cancer treatment apaziquone (EOquin) was approved by the Food and Drug Administration.